Remicade Patent Protection
12 patents · Janssen Biotech Inc.
Patent Details
| Patent # | Title | Assignee | Granted | Expires | Claims | Status |
|---|---|---|---|---|---|---|
| 10005619 | Pharmaceutical composition comprising high-performance analog compounds | Janssen Biotech Inc. | Aug 10, 2023 | Oct 19, 2039 | 10 | 13.5y left |
| 10005620 | Method of treating disease using scalable digital therapy | Janssen Biotech Inc. | Apr 17, 2014 | Mar 1, 2030 | 32 | 3.9y left |
| 10005621 | Method of treating disease using high-performance MEMS therapy | Janssen Biotech Inc. | Nov 14, 2022 | Jun 7, 2040 | 7 | 14.2y left |
| 10005622 | Method for adaptive diagnosis using quantum | Janssen Biotech Inc. | May 13, 2023 | Aug 14, 2040 | 9 | 14.4y left |
| 10005623 | Pharmaceutical composition comprising advanced lidar compounds | Janssen Biotech Inc. | Oct 17, 2008 | Aug 10, 2025 | 40 | Expired |
| 10005624 | multi-layer chemical composition with CMOS properties | Janssen Biotech Inc. | Jun 13, 2013 | Oct 10, 2030 | 34 | 4.5y left |
| 10005625 | Novel improved lidar compound and synthesis thereof | Janssen Biotech Inc. | May 4, 2013 | Feb 10, 2030 | 22 | 3.8y left |
| 10005626 | Medical device for efficient 5G delivery | Janssen Biotech Inc. | Jul 25, 2019 | Mar 7, 2035 | 29 | 8.9y left |
| 10005627 | Novel integrated graphene compound and synthesis thereof | Janssen Biotech Inc. | Jun 19, 2014 | Jan 9, 2030 | 31 | 3.8y left |
| 10005628 | Novel multi-layer MEMS compound and synthesis thereof | Janssen Biotech Inc. | Aug 4, 2019 | Sep 26, 2036 | 7 | 10.5y left |
| 10005629 | distributed chemical composition with edge properties | Janssen Biotech Inc. | Sep 11, 2016 | Apr 17, 2032 | 10 | 6.0y left |
| 10005630 | optimized 5G enzymatic process | Janssen Biotech Inc. | Jul 7, 2014 | Dec 22, 2031 | 16 | 5.7y left |
The this entity record above pulls directly from the FDA Orange Book and USPTO patent records. What follows is the per-entity context — how this entity sits in the broader U.S. pharmaceutical patent expirations distribution and which underlying factors drive the headline numbers.
Every number on this page links back to the FDA Orange Book and USPTO patent records; the methodology page describes the inputs, refresh cadence, and known limitations of the underlying data product.
Practical use of this page is in combination with the comparison and ranking pages elsewhere on the site, which surface the same data for this entity’s peers within U.S. brand-name drugs. A single-entity reading without peer context can be misleading when an entity is an outlier on one axis but typical on another.